All In Biotech

NDA 020068 · Clinigen Hlthcare

Foscavir

Foscarnet Sodium · Intravenous

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Oct 28, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Sep 27, 1991

Approved uses

4

Original approval plus efficacy supplements

Registered trials

35

8 Phase 3, 4 recruiting

FAERS reports

1,935

1,894 serious, 702 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING RENAL IMPAIRMENT IS THE MAJOR TOXICITY OF FOSCAVIR. FREQUENT MONITORING OF SERUM CREATININE, WITH DOSE ADJUSTMENT FOR CHANGES IN RENAL FUNCTION, AND ADEQUATE HYDRATION WITH ADMINISTRATION OF FOSCAVIR IS IMPERATIVE. (See ADMINISTRATION section; Hydration. ) SEIZURES, RELATED TO ALTERATIONS IN PLASMA MINERALS AND ELECTROLYTES, HAVE BEEN ASSOCIATED WITH FOSCAVIR TREATMENT. THEREFORE, PATIENTS MUST BE CAREFULLY MONITORED FOR SUCH CHANGES AND THEIR POTENTIAL SEQUELAE. MINERAL AND ELECTROLYTE SUPPLEMENTATION MAY BE REQUIRED. FOSCAVIR IS INDICATED FOR USE ONLY IN IMMUNOCOMPROMISED PATIENTS WITH CMV RETINITIS AND MUCOCUTANEOUS ACYCLOVIR-RESISTANT HSV INFECTIONS. (See INDICATIONS section).

What it is approved for

From the label in effect Dec 11, 2025.

INDICATIONS CMV Retinitis FOSCAVIR is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with FOSCAVIR and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCAVIR HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. Mucocutaneous Acyclovir Resistant HSV Infections FOSCAVIR is indicated for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. SAFETY AND EFFICACY OF FOSCAVIR HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER HSV INFECTIONS (e.g., RETINITIS, ENCEPHALITIS); CONGENITAL OR NEONATAL HSV DISEASE; OR HSV IN NONIMMUNOCOMPROMISED INDIVIDUALS.

Mechanism: Mechanism of Action Foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. Foscarnet does not require activation (phosphorylation) by thymidine kinase or other kinases.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 24, 1997 Supplement 6 · Efficacy
  • Jan 24, 1997 Supplement 7 · Efficacy
  • Jun 16, 1995 Supplement 3 · Efficacy
  • Sep 27, 1991 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • FOSCAVIR · FOSCARNET SODIUM 6GM/250ML (24MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • FOSCAVIR · FOSCARNET SODIUM 12GM/500ML (24MG/ML) · SOLUTION, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Foscarnet" as an intervention, any sponsor and status, largest first.

All 35 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use502
  • drug ineffective209
  • acute kidney injury197
  • pancytopenia190
  • cytomegalovirus infection182
  • drug resistance145
  • renal impairment124
  • pyrexia111
  • nephropathy toxic109
  • cystitis haemorrhagic100
  • encephalitis cytomegalovirus99
  • cytomegalovirus infection reactivation97

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200419
200522
200625
200721
200853
200945
201035
201179
201267
201371
201460
201547
2016110
2017158
2018149
2019183
2020159
2021112
202298
202389
2024134
2025138
202661

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 145 on PubMed

Sponsor: Clinigen Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.